PROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE JEFFRIES 2019 GLOBAL HEALTHCARE CONFERENCE ON FRIDAY, JUNE 7TH, 2019
May 20, 2019 09:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, May 20, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
PROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE COWEN CONFERENCE ON WEDNESDAY - MARCH 13, 2019
March 11, 2019 09:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 11, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
PROCESSA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA
January 29, 2019 09:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
PROCESSA PHARMACEUTICALS ANNOUNCES PRESENTATION OF PCS499 DATA AT THE ANNUAL MEETING OF AMERICAN ACADEMY OF DERMATOLOGY
January 09, 2019 09:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
PROCESSA PHARMACEUTICALS ANNOUNCES UP-LISTING TO OTCQB MARKET
December 06, 2018 09:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS BEEN ASSIGNED THE LICENSE FOR THE CLINICAL STAGE COMPOUND CTP-499 AND PLANS TO DEVELOP THE DRUG IN MULTIPLE UNMET MEDICAL NEED CONDITIONS
March 21, 2018 09:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, March 21, 2018 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTC: PCSA) announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been...